<DOC>
	<DOCNO>NCT01670370</DOCNO>
	<brief_summary>The purpose study investigate efficacy safety GemOx ( Gemcitabine Oxaliplatin ) combination rituximab ( R ) first-line treatment elderly patient aggressive B cell lymphoma .</brief_summary>
	<brief_title>Trial GemOx±R Regimen First-line Treatment Elderly Aggressive B Cell Lymphoma</brief_title>
	<detailed_description>Gemcitabine Oxaliplatin ( GemOx ) show effective activity patient relapse diffuse large-cell lymphoma solid tumor . Until clinical trial evaluate role patient elderly aggressive B cell lymphoma . The investigator therefore develop two-weekly regimen rituximab combine GemOx regimen treat elderly aggressive B cell lymphoma investigate safety efficacy . Primary Outcome Measures : - overall response rate Secondary Outcome Measures : - progression free survival - overall survival - safety toxicity Enrollment : 100 Study Start Date : January 2012 Primary Completion Date : Dec 2012</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Aggression</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1 . Histologically confirm aggressive B cell lymphoma ; 2 . Newdiagnosed untreated ; 3 . Age old 70 year old 60 year ECOG PS ≥ 2 ; 4 . Understand voluntarily sign informed consent form , able adhere study visit schedule protocol requirement . 1 . Inadequate hepatic , nephritic cardiac function : total bilirubin , ALT , AST , Cr two fold upper normal level . cardiac function Grade II ; 2 . Presence Grade III nervous toxicity two week ; 3 . HBV virus load ( HBV DNA ) &gt; 1×10E5 copies/ml ; 4 . Concomitant malignancy aggressive B cell lymphoma need treat ; 5 . Concomitant hematologic disease ( leukemia , hemophilia primary myelofibrosis ) investigator unsuitable enrol clinical trial ; 6 . Active severe infectious disease ; 7 . Major surgery within three week ; 8 . Any potential drug abuse , medical , psychological social condition may disturb investigation assessment . 9 . In condition investigator consider ineligible study . 10 . Known sensitivity allergy investigational Product .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Rituximab</keyword>
	<keyword>Gemcitabine</keyword>
	<keyword>Oxaliplatin</keyword>
	<keyword>aggressive B cell lymphoma</keyword>
</DOC>